Meteora Capital’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Meteora Capital’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$1.6K	–	505
2022 Q4	$1.6K	Buy	25,000 +5,128	+26%	+$196	﹤0.01%	320
2022 Q3	$1K	Sell	19,872 -5,128	-21%	-$298	﹤0.01%	382
2022 Q2	$2K	Buy	+25,000	New	+$5.17K	﹤0.01%	464

Meteora Capital's BIOTW Position: Q1 2023 in Review

Meteora Capital sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 25,000 shares — an estimated $1.6K sold.

Meteora Capital first reported a position in BIOTW in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Meteora Capital reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Meteora Capital sold 25,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1.6K.
Meteora Capital first reported a position in Biotech Acquisition Company Warrant in Q2 2022 and held it in 3 quarters.
Meteora Capital's Biotech Acquisition Company Warrant position peaked at $2K in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Meteora Capital's 13F filing for Q1 2023, filed 15 May 2023.